We observed that genome-wise PRS performed better in predicting BC risk than OC risk in BRCA1 PV carriers (OR = 1.37, 95% CI = 1.03–1.81, p = 0.0291 * vs. OR = 0.99, 95% CI = 0.71–1.38, p = 0.9530). The gene discussed is BRCA1; the disease is breast cancer.